Evaluation of liposomal bupivacaine versus immediate release
bupivacaine
in
post-operative
pain
after
knee
surgery
POSTER #5-191
A

B

A,B

C

Nathan Greenfield , PharmD 2015 Candidate, Saba Gidey , PharmD, BCPS, Dusty Lisi , MS, PharmD, Cristina Refec , RN, BSN
APhiladelphia

College of Osteopathic Medicine, School of Pharmacy, Suwanee, GA
BGwinnett Medical Center, Lawrenceville, GA
CGwinnett Medical Center, Duluth, GA

BACKGROUND
The management of post-operative pain holds many challenges. The use of narcotics,
including PCA (patient controlled analgesia), and femoral nerve blocks can limit ambulation,
increase the length of hospital stays, and cause adverse events that hinder overall recovery.
Liposomal bupivacaine is a non-opioid anesthetic indicated for the management of post-operative
pain. Studies have shown that the use of liposomal bupivacaine has been associated with a
decrease in opiate use after total knee arthroplasty, and can offer multimodal pain management
through the maximization of pain control while decreasing side effects. The purpose of this study
is to determine the effectiveness of using liposomal bupivacaine for patients undergoing partial or
total knee arthroplasty in comparison to femoral nerve block with or without post-operative PCA.
The development of a liposomal formulation of local anesthetics stems from the desire to alter
the pharmacokinetics of conventional local anesthetics, specifically to alter the short duration of
action. Local anesthetics typically have a short duration of action (< 7 hours), at which point
opiates are typically used to control pain3. The liposomal formulation of bupivacaine has a
duration of action that is significantly longer (~96 hours), and undergoes both short-term, firstorder absorption and longer-term zero-order absorption3,4. This leads to a two peak phenomenon
when looking at plasma concentration over time2. The clinical implications of this longer duration
and two peak phenomenon are a more sustained and progressive disruption of sensory neural
transmission.
Two articles from the Journal of Arthroplasty, as well as a review article evaluating liposomal
bupivacaine for knee replacement surgery, have described the effects of using liposomal
bupivacaine on length of stay, patient reported pain scores, and average opioid usage1,2,5. These
articles evaluate the effectiveness of liposomal bupivacaine compared to conventional therapy,
and while the articles by Surdam et al. and Harrison note a trend in improved pain scores and
decreased narcotic use, the article by Bagsby suggests that liposomal bupivacaine is not superior
to conventional therapy. This shows the continued need for research into the overall
effectiveness of liposomal bupivacaine on post-procedural pain, and how it compares to
conventional therapy.

RESULTS
Table 1: Demographics and data analysis
Control

Liposomal
Bupivacaine

P

N

50

100

Male

15

38

Female

24

58

Age (mean)

68

66

0.26

Total Knee Replacement

35

82

0.096

Partial Knee Replacements

15

18

Length of Stay (mean)

2.98

1.9

<0.0001

Time to Ambulation (mean)

1.76

0.38

<0.0001

Time to D/C from PT (mean)

3.10

1.78

<0.0001

Pain Score at 24 hours
(mean)
Pain Score at 48 hours
(mean)
PACU Morphine Equivalents
(mean)

4.69

4.11

0.18

4.46

3.71

0.078

7.00

4.89

0.085

Non-PACU Morphine
Equivalents (mean)

51.33

28.73

0.0003

Daily Morphine Equivalents
(mean)

21.11

12.65

0.0016

43

8

<0.0001

PCA Use

Figure 1: Opioid requirements (in morphine equivalents)

0.91

Figure 2: Mean Length of stay (in days)

Figure 3: Patient reported pain scores

Our data support several clinical trials, suggesting that a protocol outlining the use
of liposomal bupivacaine in knee replacement surgery may lead to better patient
outcomes and satisfaction. These data have been used as the basis for updating
current practice at Gwinnett Medical Center, leading to the addition of liposomal
bupivacaine to the formulary for use in knee replacement surgery.

The primary outcome of this study is to determine the effect liposomal bupivacaine in addition
to conventional therapy compared to conventional therapy alone on post-operative pain control
after partial or total knee replacement. Secondary outcomes evaluated included length of stay,
time to ambulation, and patient reported pain scores on post-op day 1 and day 2, in the two
patient populations.

• This is a single-center, retrospective, cohort study was conducted in a 353 bed academic
medical center
• Medical records were used to identify patients over the age of 18 who have undergone knee
replacement and received peri-operative liposomal bupivacaine in addition to conventional
therapy or conventional therapy alone
• Data on 150 patients was collected, with 100 patients receiving liposomal bupivacaine and 50
control patients
• Data on age, gender, type of surgery performed, pain scores, opiate and non-opiate pain
medications used in the post-anesthesia care unit (PACU) and post-PACU, time to ambulation
(50 feet), and length of stay was collected and analyzed
• The primary outcome of pain control was measured through morphine equivalents required
post-operatively

• A total of 150 patients who had knee arthroplasty surgery were retrospectively
evaluated, with 100 patients receiving liposomal bupivacaine injections
• Compared to the control sample, a reduction in opiate requirements, as determined
by morphine equivalents, was seen with liposomal bupivacaine post-PACU, but not
in the PACU (p = 0.0003 and p = 0.085, respectively)
• When examining secondary outcomes, a statistically significant decrease in length
of stay and time to ambulation was seen in the liposomal bupivacaine group (length
of stay: 1.9 days vs 2.98 days, p < 0.0001; time to ambulation: 0.38 days vs 1.76 days,
p < 0.0001). However, liposomal bupivacaine showed no statistical difference in pain
scores, either at 24 or 48 hours (p = 0.18 and 0.078, respectively)
• A subgroup analysis that removed patients with extended lengths of stay (two from
control and one from liposomal bupivacaine) revealed similar results. Length of stay
and daily opiate requirements remained statistically different (p <0.0002 and p =
0.0008, respectively). Opiate requirements in the PACU remained similar (p = 0.16)
• Several clinical trials have been conducted with liposomal bupivacaine in knee
replacement surgery
• A study in press by Surdam et al.1 shows that liposomal bupivacaine decreases
the opiate requirements POD1, while other reports vary regarding opiate use. A
review article by Harrison2 reports that extended release bupivacaine
significantly decreases narcotics used, while Bagsby et al.5 reports no difference
in opiate usage.
• The study by Bagsby et al. also shows that liposomal bupivacaine does not
decrease reported pain scores when compared to conventional therapy.
• The preliminary findings of a large clinical trial by Barrington and Emerson6
show that liposomal bupivacaine decreases overall length of stay.
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